European Commission Approves Capmatinib in NSCLC With MET Exon 14 Skipping Mutation

Article

Based on results from the phase 2 GEOMETRY mono-1 trial, the European Commission has approved capmatinib for patients with non–small cell lung cancer who have MET exon 14 skipping mutations, and a need for systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy.

The European Commission has approved capmatinib (Tabrecta) for adults with non–small cell lung cancer (NSCLC) who have a MET exon 14 skipping mutation and need for systemic therapy after prior treatment with immunotherapy and/or platinum-based chemotherapy, according to a press release from Novartis.1

Results from the phase 2 GEOMETRY mono-1 trial (NCT02414139) led to the approval, and patients received either capmatinib as either second-line treatment (n = 30) or later (n = 1).Among the 31 patients enrolled, the confirmed response rate (ORR) was 51.6% (95% CI, 33.1%-69.8%), with a rate of 44.0% (95% CI, 34.1%-54.3%) among those who received 1 or more prior lines of therapy.

The most common treatment-related adverse effects observed in 20% or more of the population were peripheral edema, nausea, fatigue, increased blood creatinine, vomiting, dyspnea, decreased appetite, and back pain.

“As the leading cause of cancer-related deaths worldwide, lung cancer can be a devastating diagnosis for patients and their families,” Marie-France Tschudin, president of Innovative Medicines International and chief commercial officer at Novartis, said in the press release. “With this new targeted therapy that treats a specific mutation driving cancer growth, we are delivering a much-needed treatment option and bringing hope to patients with this challenging disease.”

In May 2020, the FDA granted accelerated approval to capmatinib for patients with NSCLC who have a MET exon 14 skipping mutation, which is indicated by a FoundationOne CDx assay.2

References

  1. Novartis received European Commission approval for Tabrecta for the treatment of METex14 skipping advanced non–small cell lung cancer. News Release. Novartis. June 22, 2022. Accessed June 22, 2022. https://bit.ly/3ya8r2V
  2. FDA grants accelerated approval to capmatinib for metastatic non–small cell lung cancer. News Release. FDA. May 6, 2020. Accessed June 22, 2022. https://bit.ly/3xJGde4
Recent Videos
Patrick Oh, MD, highlights next steps for further research in treating patients with systemic therapy in addition to radiotherapy for early-stage NSCLC.
Increased use of systemic therapies, particularly among patients with high-risk node-negative NSCLC, were observed following radiotherapy.
Interest in novel therapies to improve outcomes initiated an investigation of the use of immunotherapy in early-stage non-small cell lung cancer.
Higher, durable rates of response to frontline therapy are needed to potentially improve long-term survival among patients with non–small cell lung cancer.
Martin Dietrich, MD, PhD, and Wade T. Iams, MD, experts on lung cancer
Martin Dietrich, MD, PhD, and Wade T. Iams, MD, experts on lung cancer
Martin Dietrich, MD, PhD, and Wade T. Iams, MD, experts on lung cancer
Martin Dietrich, MD, PhD, and Wade T. Iams, MD, experts on lung cancer
Martin Dietrich, MD, PhD, and Wade T. Iams, MD, experts on lung cancer
Martin Dietrich, MD, PhD, and Wade T. Iams, MD, experts on lung cancer
Related Content
Data from KEYNOTE-868 and KEYNOTE-A18 support the approval of pembrolizumab-based therapy in endometrial and cervical cancer, respectively.

Pembrolizumab Regimens Earn European Approvals in Gynecologic Cancers

Russ Conroy
October 24th 2024
Article

Data from KEYNOTE-868 and KEYNOTE-A18 support the approval of pembrolizumab-based therapy in endometrial and cervical cancer, respectively.

Terence T. Sio, MD, MS, highlights advances such as proton beam radiotherapy that may improve outcomes for those with non–small cell lung cancer.

Optimizing NSCLC Outcomes Via Technological Advances in Radiation Oncology

Terence T. Sio, MD, MS
June 3rd 2024
Podcast

Terence T. Sio, MD, MS, highlights advances such as proton beam radiotherapy that may improve outcomes for those with non–small cell lung cancer.

Expert Commentary on the Product Profile of Lazertinib in NSCLC

Expert Commentary on the Product Profile of Lazertinib in NSCLC

Jenan Dailey, PharmD, BCAP
October 23rd 2024
Article

Jenan Dailey, PharmD, BCAP, spoke about the approval of lazertinib plus amivantamab as first-line treatment for patients with locally advanced or metastatic NSCLC.

Richard Lazzaro, MD, discusses how a robot-assisted platform has impacted his thoracic surgery and highlights other potential advancements in the field.

Moving The Needle in Lung Cancer Management With Robotic-Assisted Surgery

Richard Lazzaro, MD
April 22nd 2024
Podcast

Richard Lazzaro, MD, discusses how a robot-assisted platform has impacted his thoracic surgery and highlights other potential advancements in the field.

Data from the phase 2 SAVANNAH trial may support savolitinib as a new treatment option following standard-of-care osimertinib in EGFR-mutated NSCLC.

Osimertinib/Savolitinib Shows Meaningful Responses in EGFR+ NSCLC

Russ Conroy
October 16th 2024
Article

Data from the phase 2 SAVANNAH trial may support savolitinib as a new treatment option following standard-of-care osimertinib in EGFR-mutated NSCLC.

Support for the approval comes from phase 3 LUNAR study findings indicating TTFields significantly prolonged OS compared with standard of care alone.

FDA Approves TTFields for Previously Treated Metastatic NSCLC

Roman Fabbricatore;Russ Conroy
October 15th 2024
Article

Support for the approval comes from phase 3 LUNAR study findings indicating TTFields significantly prolonged OS compared with standard of care alone.